1. Medtech Insight
  2. >>Device Area

MDxHealth Prostate Cancer Test Identifies Increased Risk of Cancer Recurrence

 
• By Catherine Longworth

MDxHealth has released results from a prospective study demonstrating biomarkers from its Confirm MDx prostate cancer test identifies men at increased risk of prostate cancer recurrence. The test could help urologists monitor therapy response to improve the personalized treatment of castration resistant prostate cancer (CRPC).

Cancer cell division of two prostate cancer cells in the final stage of cell division (cytokinesis) cytoplasm divides. the cells are joined by several thin cytoplasmic bridges. They to form tumours
Prostate cancer cell division • Source: Shutterstock

MDxHealth SA's Confirm MDx prostate cancer test identified men at increased risk of prostate cancer recurrence in a prospective study, suggesting the tissue-based test could help urologists monitor therapy response to improve the personalized treatment of castration resistant prostate cancer (CRPC).

Jack Schalken, director of urological research at the Radboud University in the Netherlands presented results from the study at the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Oncology

More from Device Area

Blood Volume, Reimagined: Daxor’s BVA Could Slash Testing Time and Save Lives

 
• By Elizabeth Orr

The Daxor Blood Volume Analysis (BVA) is aimed at improving care for heart failure patients. It will allow blood volume to be measured from the patient’s bedside for the first time and is also significantly faster than earlier testing methods.

Dexcom Pushes Forward With R&D Growth, New Devices Amid Scrutiny And Shake-Up

 
• By Marion Webb

Dexcom has endured recalls, layoffs and leadership change, but interim CEO Jake Leach said the company remains committed to innovating next-gen devices.

Whistleblower Suit Against UnitedHealth Continues After Semler, Bard Settle Related Cases

 
• By Elizabeth Orr

Insurance firm UnitedHealth is facing allegations the company intentionally used an unreliable PAD screening method to increase its reimbursements under Medicare Advantage. Semler Scientific and Bard, which respectively made and manufactured the products in question, settled related cases for $37m.